Core Viewpoint - Rapport Therapeutics, a clinical-stage biotechnology company, is focused on developing small molecule precision medicines for neurological and psychiatric disorders and will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1]. Company Overview - Rapport Therapeutics is dedicated to discovering and developing small molecule precision medicines specifically for patients with neurological or psychiatric disorders [3]. - The company's founders have made significant discoveries regarding receptor associated proteins (RAPs) in the brain, which underpin Rapport's RAP technology platform [3]. - The precision neuroscience pipeline includes the lead investigational drug, RAP-219, which targets a RAP expressed in specific brain regions, aiming to treat drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [3]. - Additional programs are in preclinical and late-stage discovery phases, focusing on chronic pain and hearing disorders [3].

Company Overview - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for central nervous system (CNS) disorders [6] - The company utilizes a unique RAP technology platform that targets receptor associated proteins (RAPs) in the brain, aiming to create precision small molecule candidates that address limitations in conventional neurology drug discovery [6] Leadership Appointment - Dr. Jeffrey Sevigny has been appointed as the chief medical officer (CMO) of Rapport Therapeutics, bringing over 15 years of experience in translational and clinical drug development [1][2] - Dr. Sevigny previously served as CMO at Prevail Therapeutics and held senior roles at Eli Lilly, where he contributed to significant corporate successes including financing rounds, an IPO, and an acquisition [2][4] Clinical Strategy and Pipeline - As CMO, Dr. Sevigny will oversee the clinical strategy and advancement of Rapport's pipeline, particularly the RAP-219 program, which is currently in clinical trials for conditions such as focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania [3][6] - The RAP-219 program is noted for its compelling Phase 1 data and aims to achieve neuroanatomical specificity by selectively targeting RAPs expressed in specific brain regions [5][6] Company Vision and Goals - The CEO of Rapport, Abraham N. Ceesay, expressed confidence in Dr. Sevigny's ability to lead the clinical development team and emphasized the importance of collaboration with regulatory authorities and patient advocacy organizations [4] - Dr. Sevigny highlighted the company's strong scientific foundation and the potential of its clinical candidates to provide transformative treatment options for patients with neurological disorders [5]